| Zacks Company Profile for Biostar Pharmaceuticals, Inc. (BSPM : OTC) |
|
|
| |
| • Company Description |
| BioStar Pharmaceuticals, Inc., through its wholly-owned subsidiary, Shaanxi Aoxing Pharmaceutical Co., Ltd., develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based over-the-counter products, two prescription-based pharmaceuticals and ten nutrients. The Company has adopted international standards and is in the process of applying for three patents. It also operates an herbal medicine planting base which provides it with many of its needed materials at a significantly lower cost than purchasing from third parties, and eliminates most needs for transportation.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 343 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: -2.30 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
NO. 588 SHIJI XI AVENUE
-
XIANYANG,F4 712046
CHN |
ph: 011-86-29-3368-6638
fax: - |
None |
http://www.biostarpharmaceuticals.com |
|
|
| |
| • General Corporate Information |
Officers
Ronghua Wang - Chief Executive Officer and President
Xiaojuan Zhai - Chief Financial Officer
Qinghua Liu - Director
Haipeng Wu - Director
King-fai Leung - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 090678301
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 2.00 (0.14:1)
Beta: -2.30
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
